Skip to main content
. 2024 Oct 3;110(3):629–639. doi: 10.3324/haematol.2024.286040

Table 2.

Comparison of baseline patient characteristics between granulocyte colony-stimulating factor/antithymocyte globulin group 2 and the post-transplantation cyclophosphamide with low-dose antithymocyte globulin group after propensity score matching analysis.

graphic file with name 110629.tab2.jpg